This site may receive compensation from the provider linked above. Full disclosure.
Weight loss and GLP-1 providers currently serving Lagrange County, Indiana — sourced from Google Business listings.
Medical clinic
410 Sawyer Rd, Kendallville, IN 46755
Social services organization
304 N 00Ew, LaGrange, IN 46761
Business listings sourced from Google Maps. Information may not be current.
GLP-1 telehealth services are available to residents of all communities in Lagrange County, Indiana. Select your city for local information.
Lagrange County is a county in Indiana with a population of approximately 39,614 residents. Our telehealth platform connects patients across all communities in Lagrange County with board-certified physicians who can prescribe FDA-approved GLP-1 medications online. Indiana's Rust Belt cities and agricultural communities face a dual obesity crisis. The Indianapolis metro has boomed while Gary, Evansville and rural southern Indiana counties have seen obesity rates climb above 40%, making telehealth GLP-1 access critically important.
GLP-1 receptor agonists — including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — are clinically proven weight loss medications. Indiana ranks 7th nationally for adult obesity at 36.8%. Type 2 diabetes affects over 700,000 Hoosiers. Marion County (Indianapolis) alone has over 150,000 adults eligible for GLP-1 therapy. Patients in Lagrange County can now access these treatments through a simple online consultation, without the need to travel to an in-person clinic.
Access Ozempic, Wegovy, Mounjaro, and Zepbound — all FDA-approved GLP-1 medications proven to support significant weight loss in clinical trials.
All prescribing physicians in our network hold active Indiana medical licenses. Consultations comply with Indiana telehealth law (Indiana Code § 25-1-9.5).
Our simple 3-step process makes getting a GLP-1 prescription easy for Lagrange County residents.
GLP-1 telehealth services are available across all Indiana counties. Browse neighboring counties below.
Explore GLP-1 telehealth availability across Indiana's major cities.
Yes. Indiana law permits telehealth prescriptions for GLP-1 medications after a proper clinical evaluation under Indiana Code § 25-1-9.5. Our network of Indiana-licensed physicians can complete your consultation online and send a prescription to your preferred pharmacy in Lagrange County or arrange home delivery.
Patients in Lagrange County can be prescribed semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), and liraglutide (Saxenda®) — all FDA-approved GLP-1 receptor agonists indicated for weight management. Your physician will recommend the most appropriate option based on your health profile.
Consultation fees vary by provider, typically ranging from $0 to $199 for the initial visit. Medication costs depend on insurance coverage, manufacturer savings programs, and pharmacy choice. Many patients in Indiana qualify for significant savings through patient assistance programs.
After completing your online health assessment, most patients in Lagrange County receive a physician response within 24–48 hours. If approved, your prescription can be sent to a pharmacy near you in Lagrange County or shipped directly to your home within 2–5 business days.
Lagrange County has several local weight loss clinics and medical practices that may offer GLP-1 treatments in person. However, our telehealth service provides the same quality of care from the convenience of your home, with licensed Indiana physicians available to patients throughout Lagrange County.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
